Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.84
Schlusskurs vom Vortag:
$4.84
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$633.18M
Einnahmen:
$25.81M
Nettoeinkommen (Verlust:
$-188.12M
KGV:
0.00
EPS:
-1.4747
Netto-Cashflow:
$-183.77M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$6.49
Exscientia Plc Adr Stock (EXAI) Company Profile
Firmenname
Exscientia Plc Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie EXAI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EXAI
Exscientia Plc Adr
|
0.00 | 633.18M | 25.81M | -188.12M | -183.77M | -1.4747 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Exscientia Plc Adr Stock (EXAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-09 | Eingeleitet | TD Cowen | Buy |
| 2024-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
Exscientia Plc Adr Aktie (EXAI) Neueste Nachrichten
Exscientia's SWOT analysis: ai biotech stock faces merger challenges - Investing.com India
Exscientia's SWOT analysis: ai biotech stock faces merger challenges By Investing.com - Investing.com South Africa
Exscientia's SWOT analysis: ai-driven biotech stock faces merger challenges - Investing.com
Exscientia and Recursion Merge to Revolutionize Drug Discovery - TipRanks
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition - Investing.com
Recursion Pharmaceuticals secures stockholder nod for Exscientia acquisition By Investing.com - Investing.com UK
Recursion, Exscientia shareholders back merger - Investing.com
Such Is The Power Of Verizon Communications Inc (NYSE: VZ) - Stocks Register
Exscientia advances two drug programs with Sanofi By Investing.com - Investing.com South Africa
Exscientia advances two drug programs with Sanofi - Investing.com
Recursion’s All-Stock Acquisition of Exscientia plc (EXAI): NVIDIA-Backed Merger to Revolutionize AI-Driven Drug Discovery - Yahoo Finance
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains? - Nasdaq
Exscientia's SWOT analysis: AI biotech stock faces merger, pipeline milestones - Investing.com
Recursion Pharmaceuticals secures key shareholder support - Investing.com
AI biotechs Exscientia and Recursion agree $688m merger - pharmaphorum
Amazon (AMZN) Plunges 19.1% in a Month: Should You Buy the Dip? - Yahoo Finance
Why Do Hedge Funds Think That Exscientia plc (EXAI) Will Skyrocket? - Yahoo Finance
Exscientia takes full control of cancer drug program - Investing.com
Can Exscientia (EXAI) Climb 57.17% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Exscientia (EXAI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
3 Small-Cap Stocks to Invest in AI Drug Development - TradingView
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
New Strong Buy Stocks for October 25th - Yahoo Finance
Sanofi-Aventis S.A. ADR (SNY-Q) QuotePress Release - The Globe and Mail
Exscientia (NASDAQ:EXAI) shareholders have endured a 55% loss from investing in the stock a year ago - Yahoo Finance
Exscientia Ltd ADR Stock Quote | Stock Price for EXAI - Financial Content
Exscientia (EXAI) Stock Price, News & Analysis - MarketBeat
Finanzdaten der Exscientia Plc Adr-Aktie (EXAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):